APA

D'Arena G., Simeon V., Laurenti L., Cimminiello M., Innocenti I., Gilio M., Padula A., Vigliotti M. L., De Lorenzo S., Loseto G., Passarelli A., Di Minno M. N. D., Tucci M., De Feo V., D'Auria F., Silvestris F., Di Minno G. & Musto P. (20180417). Adverse drug reactions after intravenous rituximab infusion are more common in hematologic malignancies than in autoimmune disorders and can be predicted by the combination of few clinical and laboratory parameters: results from a retrospective, multicenter study of 374 patients. : Leukemia & lymphoma.

Chicago

D'Arena Giovanni, Simeon Vittorio, Laurenti Luca, Cimminiello Michele, Innocenti Idanna, Gilio Michele, Padula Angela, Vigliotti Maria Luigia, De Lorenzo Sonya, Loseto Giacomo, Passarelli Anna, Di Minno Matteo Nicola Dario, Tucci Marco, De Feo Vincenzo, D'Auria Fiorella, Silvestris Francesco, Di Minno Giovanni and Musto Pellegrino. 20180417. Adverse drug reactions after intravenous rituximab infusion are more common in hematologic malignancies than in autoimmune disorders and can be predicted by the combination of few clinical and laboratory parameters: results from a retrospective, multicenter study of 374 patients. : Leukemia & lymphoma.

Harvard

D'Arena G., Simeon V., Laurenti L., Cimminiello M., Innocenti I., Gilio M., Padula A., Vigliotti M. L., De Lorenzo S., Loseto G., Passarelli A., Di Minno M. N. D., Tucci M., De Feo V., D'Auria F., Silvestris F., Di Minno G. and Musto P. (20180417). Adverse drug reactions after intravenous rituximab infusion are more common in hematologic malignancies than in autoimmune disorders and can be predicted by the combination of few clinical and laboratory parameters: results from a retrospective, multicenter study of 374 patients. : Leukemia & lymphoma.

MLA

D'Arena Giovanni, Simeon Vittorio, Laurenti Luca, Cimminiello Michele, Innocenti Idanna, Gilio Michele, Padula Angela, Vigliotti Maria Luigia, De Lorenzo Sonya, Loseto Giacomo, Passarelli Anna, Di Minno Matteo Nicola Dario, Tucci Marco, De Feo Vincenzo, D'Auria Fiorella, Silvestris Francesco, Di Minno Giovanni and Musto Pellegrino. Adverse drug reactions after intravenous rituximab infusion are more common in hematologic malignancies than in autoimmune disorders and can be predicted by the combination of few clinical and laboratory parameters: results from a retrospective, multicenter study of 374 patients. : Leukemia & lymphoma. 20180417.